Barclays Maintains Overweight on Tandem Diabetes Care, Raises Price Target to $60

Tandem Diabetes Care, Inc. -0.53%

Tandem Diabetes Care, Inc.

TNDM

30.11

-0.53%

Barclays analyst Matt Miksic maintains Tandem Diabetes Care (NASDAQ: TNDM) with a Overweight and raises the price target from $58 to $60.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via